Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Di… (NCT06747572) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
United States, Belgium, Canada401 participantsStarted 2024-12-19
Plain-language summary
The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.
Who can participate
Age range
12 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Key Inclusion Criteria:
* Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 30 milliliter per minute (mL/min)/1.73 m\^2
* Willing and able to comply with scheduled visits and other study procedures
* A pre-existing diagnosis of ADPKD as defined in the protocol
Key Exclusion Criteria:
* History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
* History of solid organ or bone marrow transplantation or nephrectomy
* Ongoing renal replacement therapy or planning to start renal replacement therapy less than or equal to (≤)12 months from the Genotyping Visit in Part A
Other protocol defined Inclusion/Exclusion criteria will apply.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Part A: Percentage of PKD1 Gene Variant Groups in the ADPKD Population
Timeframe: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
2
Part A: Weight of Participants Within Each PKD1 Gene Variant Group
Timeframe: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
3
Part A: Height of Participants Within Each PKD1 Gene Variant Group
Timeframe: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
4
Part A: Body Mass Index (BMI) of Participants Within Each PKD1 Gene Variant Group
Timeframe: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)
5
Part A: Age of Participants at ADPKD Diagnosis Within Each PKD1 Gene Variant Group
Timeframe: Genotyping Visit on Day 1 of Part A (Part A duration: 1 Calendar Day)